Publication Topic

Preib MT, Emden MR, Sacks NC, Mitrani-Gold FS, Ju S, Kawano Y, Kawamatsu S, Joshi AV. 2025. Prevalence and economic evaluation of acute uncomplicated cystitis in women from Japan: A retrospective cohort study. JAC Antimicrob Resist 7(5):dlaf178; doi: 10.1093/jacamr/dlaf178. PMID: 41113066.

Desai NR, Fermann G, Pollack C, Venkatesh A, Hooda N, Jiang X, Sacks N, Holtz A, et al. Emergency department visits for PSVT: An analysis of the HCUP Nationwide Emergency Department Sample. Abstract 391, American College of Emergency Physicians (ACEP) Research Forum, Salt Lake City, UT. Ann Emerg Med 86(3S1):S169; doi: 10.1016/j.annemergmed.2025.06.409, September 2025.

Duong T, Haselkorn T, Miller B, Coats J, Jensen I, Ward E, Wood M, Graham RJ, Servais L. 2025. A real-world analysis of the impact of X-linked myotubular myopathy on caregivers in the United States. Orphanet J Rare Dis 20(1):224. doi: 10.1186/s13023-025-03583-w.

Desai NR, Piccini JP, Sacks NC, Reichert H, Hooda N, Jiang X, Blood AJ, Holz A, et al. Emergency department visits and inpatient admissions for atrial fibrillation in the United States (US): 2015-2019. Abstract I10, Academy of Managed Care Pharmacy (AMCP) Annual Meeting, Houston, TX. J Manag Care Spec Pharm 31(3-a Suppl):S74; doi: 10.18553/jmcp.2025.31.3-a.s1, March 31-April 3, 2025.

Tao C, Nicholson G, Desai N, Sacks N, Sherwood R, Pokorney S. Budget impact of etripamil for the treatment of paroxysmal supraventricular tachycardia (PSVT) in the United States. Abstract I9, AMCP Annual Meeting, Houston, TX. J Manag Care Spec Pharm 31(3-a Suppl):S73; doi: 10.18553/jmcp.2025.31.3-a.s1, March 21-April 3, 2025.

Nordyke RJ, Motyka J, Patterson JA. 2025. The association of 340B program drug margins with covered entity characteristics. Inquiry 62(Jan-Dec):469580251324051; doi: 10.1177/00469580251234051. PMID: 4012322.

Shafrin J, Wang S, Sharma K, Spurrier K, Nordyke RJ. 2025. Will the Institute for Clinical and Economic Review’s shared savings approach decrease value-based prices most for the most severe diseases? Value Health 28(1):25-30; doi: 10.1016/j.val.2024.09.002. PMID: 39357669.

Olaye A, Bean K, Velikanova R, Wolters S, Miller B, Jensen I, Pang F. Cost-effectiveness of atidarsagene autotemcel (ARSA-CEL) gene therapy for treating metachromatic leukodystrophy (MLD) in Ireland, Belgium, and the Netherlands as a part of the Beneluxa Initiative. Abstract EE693, ISPOR Europe 2024, November 2024.

Haselkorn T, Hughes W, Lennox A, Schara-Schmidt U, Roca A, Miller B, Jensen I, et al. Real-world impact of X-linked myotubular myopathy (XLMTM) on caregivers in the United Kingdom (UK), Germany, and Spain. Abstract PCR257, ISPOR EU 2024 (Top 5% Finalist).

Haselkorn T, Roca A, Miller B, Jensen I, Solomon F, Sanchez-de la Rosa R, Picart JM, Nascimento A. A real-world impact of X-linked myotubular myopathy (XLMTM) on caregivers in Spain. Presented at LXXVI Reunion Annual de la Sociedad Espanola de Nurologica, 19–23 November 2024.